Establishment and Characterization of an Epstein-Barr Virus-positive Cell Line from a Non-keratinizing Differentiated Primary Nasopharyngeal Carcinoma

• Published in: Cancer research communications Vol. 4; no. 3; pp. 645 - 659
• Main Authors: Chai, Annie Wai Yeeng, Yee, Shi Mun, Lee, Hui Mei, Abdul Aziz, Norazlin, Yee, Pei San, Marzuki, Marini, Wong, Ka Wo, Chiang, Alan K S, Chow, Larry Ka-Yue, Dai, Wei, Liu, Teng Fei, Tan, Lu Ping, Khoo, Alan Soo Beng, Lo, Kwok Wai, Lim, Paul V H, Rajadurai, Pathmanathan, Lightfoot, Howard, Barthorpe, Syd, Garnett, Mathew J, Cheong, Sok Ching
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research 04.03.2024
• Subjects: Animals; Cell Line, Tumor; Drug Mechanisms; Epstein-Barr Virus Infections - complications; Genome Biology; Head, Neck & Oral Cancers; Herpesvirus 4, Human - genetics; Mice; Nasopharyngeal Carcinoma - genetics; Nasopharyngeal Neoplasms - genetics; Preclinical Models; Rare Cancers
• ISSN: 2767-9764; 2767-9764
• DOI: 10.1158/2767-9764.CRC-23-0341

Nasopharyngeal carcinoma (NPC), a cancer that is etiologically associated with the Epstein-Barr virus (EBV), is endemic in Southern China and Southeast Asia. The scarcity of representative NPC cell lines owing to the frequent loss of EBV episomes following prolonged propagation and compromised authenticity of previous models underscores the critical need for new EBV-positive NPC models. Herein, we describe the establishment of a new EBV-positive NPC cell line, designated NPC268 from a primary non-keratinizing, differentiated NPC tissue. NPC268 can undergo productive lytic reactivation of EBV and is highly tumorigenic in immunodeficient mice. Whole-genome sequencing revealed close similarities with the tissue of origin, including large chromosomal rearrangements, while whole-genome bisulfite sequencing and RNA sequencing demonstrated a hypomethylated genome and enrichment in immune-related pathways, respectively. Drug screening of NPC268 together with six other NPC cell lines using 339 compounds, representing the largest high-throughput drug testing in NPC, revealed biomarkers associated with specific drug classes. NPC268 represents the first and only available EBV-positive non-keratinizing differentiated NPC model, and extensive genomic, methylomic, transcriptomic, and drug response data should facilitate research in EBV and NPC, where current models are limited. NPC268 is the first and only EBV-positive cell line derived from a primary non-keratinizing, differentiated nasopharyngeal carcinoma, an understudied but important subtype in Southeast Asian countries. This model adds to the limited number of authentic EBV-positive lines globally that will facilitate mechanistic studies and drug development for NPC.